Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-gamma and Nivolumab in Advanced Solid Tumors
NCT02614456Phase 1Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of interferon gamma-1b in solid tumor (advanced stage), renal cell carcinoma (RCC) and urothelial carcinoma (UC), sponsored by Fox Chase Cancer Center. Primary endpoints: Number of participants with treatment-related adverse events at 58 weeks and Recommended Phase 2 Dose at 6 weeks. Started Dec 2015; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
solid tumor (advanced stage)renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02614456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614456.